• EMD Serono is continuing to conduct safety surveillance to identify and evaluate drug safety risks
• As of 15 January 2021, 273 suspected cases of COVID-19 occurring in patients treated with Cladribine Tablets have been reported to the Merck KGaA, Darmstadt, Germany safety database
• Of these 273 cases, 161 cases are positively confirmed COVID-19
'Medically significant’ specified by the case reporter aIncludes 11 patients with compatible COVID-19 symptoms but not evaluated further given negative PCR test (3 cases considered serious); bIncludes 18 patients who were asymptomatic (2 cases considered serious); cIncludes 9 cases with compatible COVID-19 symptoms and pending outcome (1 case considered serious); dfollow-up ongoing
DJ and AN are employees of Merck KGaA, Darmstadt, Germany. AG is an employee of Merck, Aubonne, Switzerland, a division of Merck KGaA, Darmstadt, Germany.
• Letter to the editor reporting outcomes of patients receiving Cladribine Tablets who have contracted COVID-19 and have been reported to the Merck KGaA, Darmstadt, Germany Global Patient Safety Database (data cut-off 29 June 2020)